Join host and HRS Digital Education Committee Member Melissa Middeldorp, MPH, PhD and her guests Rod Passman, MD, FHRS, and Emma Svenberg, MD, PhD, live at HRX 2025.
In this episode, they explore the AMALFI Randomized Clinical Trial, which evaluated whether remote, wearable-based screening can effectively detect asymptomatic atrial fibrillation in high-risk adults. The discussion breaks down the study design, key findings, and implications for population-level AF screening strategies. It also examines how emerging digital health tools may integrate into routine cardiovascular prevention.
Learning Objectives
-
Describe the design, patient population, and primary outcomes of the AMALFI Randomized Clinical Trial.
-
Evaluate the effectiveness of remote wearable monitoring compared with usual care for detecting asymptomatic atrial fibrillation.
-
Discuss the potential clinical and health-system implications of implementing large-scale remote AF screening in high-risk populations.
Article Authors
Rohan Wijesurendra, DPhil, Guilherme Pessoa-Amorim, DPhil, Georgina Buck, MSc,Charlie Harper, DPhil, Richard Bulbulia, MD, Alison Offer, PhD, Nicholas R. Jones, DPhil, Christine A’Court, MA, Rijo Kurien, MSc, Karen Taylor, MSc, Barbara Casadei, DPhil, Louise Bowman, MD.
Podcast Contributors
Melissa E. Middeldorp, MPH, PhD
Rod S. Passman, MD, FHRS
Emma Svennberg, MD, PhD
Speaker and Article Information: Download
Listen on Heart Rhythm 365
Listen on the Innovation Hub
Listen on iHeart
Listen on Spotify
Listen on Apple Podcasts
Topic
- The Lead
Resource Type
- Podcasts
Related Resources
Podcasts
HRX NeXt Ep. 2 – A Discussion about Evolving Role of Artificial Intelligence in Healthcare
November 17, 2025
Podcasts
HRX NeXt Ep. 1 – A Discussion on HRS call-to-action: Improved MRI access for Patients with Cardiovascular implantable electronic devices.
November 17, 2025
Podcasts
The Lead Episode 126 A Discussion of Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC)
November 13, 2025